Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension study

被引：0

作者：

Vermeire, S. ^{[1
]}

Dignass, A. ^{[2
]}

Colombel, J. F. ^{[3
]}

Jain, A. ^{[4
]}

Canavan, J. B. ^{[4
]}

Wu, H. ^{[4
]}

Lawlor, G. ^{[4
]}

Osterman, M. T. ^{[4
]}

Rubin, D. T. ^{[5
]}

Regueiro, M. ^{[6
]}

机构：

[1] Univ Leuven, Chron Dis & Metab, Leuven, Belgium

[2] Goethe Univ, Med, Agaples Markus Hosp, Frankfurt, Germany

[3] Icahn Sch Med Mt Sinai, Gastroenterol, New York, NY USA

[4] Bristol Myers Squibb, Clin Res, Princeton, NJ USA

[5] Univ Chicago, Gastroenterol, Med Inflammatory Bowel Dis Ctr, Chicago, IL USA

[6] Cleveland Clin, Digest Dis & Surg Inst, Cleveland, OH USA

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

DOP39

引用

页码：I103 / I104

页数：2